BIO Share Price

Open 17.20 Change Price %
High 17.35 1 Day 0.05 0.29
Low 17.10 1 Week 0.20 1.18
Close 17.20 1 Month 0.53 3.18
Volume 9804 1 Year 2.54 17.33
52 Week High 17.75
52 Week Low 12.03
BIO Important Levels
Resistance 2 17.43
Resistance 1 17.34
Pivot 17.22
Support 1 17.06
Support 2 16.97
ETR Germany Most Active Stocks
EOAN 7.35 1.52%
EOAN 7.35 1.52%
DBK 17.52 0.23%
DBK 17.52 0.23%
CBK 7.50 0.67%
CBK 7.50 0.67%
LHA 11.69 -1.02%
DTE 16.27 0.12%
DTE 16.27 0.12%
DTE 16.27 0.12%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
5M71 39.00 13.70%
SNG 6.50 13.04%
SNG 6.50 13.04%
RTC 1.92 12.94%
PCR 7.30 7.35%
PCR 7.30 7.35%
VWSA 23.10 7.04%
BEO 3.38 6.96%
ANO 0.47 6.82%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
PES 6.73 -28.33%
PES 6.73 -28.33%
CCO 10.76 -12.66%
CCO 10.76 -12.66%
CCO 10.76 -12.66%
More..

Biotest AG (ETR: BIO)

BIO Technical Analysis 5
As on 18th Jan 2017 BIO Share Price closed @ 17.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 16.55 & Strong Buy for SHORT-TERM with Stoploss of 16.69 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO Address
BIO
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.